Smoking cessation with varenicline, a selective alpha 4 beta 2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.

MLA

Nides M, et al. “Smoking Cessation with Varenicline, a Selective Alpha 4 Beta 2 Nicotinic Receptor Partial Agonist: Results from a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial with 1-Year Follow-Up.” Archives of Internal Medicine, vol. 166, no. 15, Aug. 2006, pp. 1561–68. EBSCOhost, https://doi.org/10.1001/archinte.166.15.1561.

APA

Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR, & Varenicline Study Group. (2006). Smoking cessation with varenicline, a selective alpha 4 beta 2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine, 166(15), 1561–1568. https://doi.org/10.1001/archinte.166.15.1561

Chicago

Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR, and Varenicline Study Group. 2006. “Smoking Cessation with Varenicline, a Selective Alpha 4 Beta 2 Nicotinic Receptor Partial Agonist: Results from a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial with 1-Year Follow-Up.” Archives of Internal Medicine 166 (15): 1561–68. doi:10.1001/archinte.166.15.1561.